View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
Sponsored by Ce3

Cost-Effective Way to De-Risk Biomarker Clinical Trials

Free White Paper

Cost-Effective Way to De-Risk Biomarker Clinical Trials

By Ce3

Cost-Effective Way to De-Risk Biomarker Clinical Trials

By Ce3
Enter your details to receive the free paper:

This free white paper discusses the early development considerations when considering cost-effective ways to de-risk biomarker clinical trials.

Using a diagnostic assay during early drug development decreases enrolment costs and shortens trial timelines by focusing on target patient population.

Trial failure is also minimised as the right patient, treatment, time and dose are identified. In addition, drug and assay development timelines are coordinated such as for applications for accelerated approval or breakthrough designation.

However, the assay takes time to develop, so coordination is key. It also requires an additional investment in the early development phase.

Download this white paper to find out more.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology